Cargando…
Ibrutinib for B cell malignancies
Research over the role of Bruton’s agammaglobulinemia tyrosine kinase (BTK) in B-lymphocyte development, differentiation, signaling and survival has led to better understanding of the pathogenesis of B-cell malignancies. Down-regulation of BTK activity is an attractive novel strategy for treating pa...
Autores principales: | Novero, Aileen, Ravella, Pavan M, Chen, Yamei, Dous, George, Liu, Delong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3913970/ https://www.ncbi.nlm.nih.gov/pubmed/24472371 http://dx.doi.org/10.1186/2162-3619-3-4 |
Ejemplares similares
-
Ibrutinib and novel BTK inhibitors in clinical development
por: Akinleye, Akintunde, et al.
Publicado: (2013) -
Targets for Ibrutinib Beyond B Cell Malignancies
por: Berglöf, A., et al.
Publicado: (2015) -
MEK and the inhibitors: from bench to bedside
por: Akinleye, Akintunde, et al.
Publicado: (2013) -
Managing Ibrutinib-Intolerant Patients With B-Cell
Malignancies
por: Muñoz, Javier, et al.
Publicado: (2023) -
Ibrutinib repurposing: from B-cell malignancies to solid tumors
por: Massó-Vallés, Daniel, et al.
Publicado: (2016)